blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3861985

EP3861985 - COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.04.2024
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  12.05.2023
FormerGrant of patent is intended
Status updated on  03.04.2023
FormerExamination is in progress
Status updated on  15.03.2023
FormerGrant of patent is intended
Status updated on  06.02.2023
FormerExamination is in progress
Status updated on  12.08.2021
FormerRequest for examination was made
Status updated on  09.07.2021
Most recent event   Tooltip26.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 28.01.2026  [2026/05]
Applicant(s)For all designated states
Ocular Therapeutix, Inc.
24 Crosby Drive
Bedford, MA 01730 / US
[2021/32]
Inventor(s)01 / GOLDSTEIN, Michael
3 Hurlbut Street
Cambridge, MA 02138 / US
02 / BLIZZARD, Charles D.
6 Danbury Road
Nashua, NH 03064 / US
03 / DESAI, Ankita
41 Jacob Way
Reading, MA 01867 / US
04 / DRISCOLL, Arthur
14 Grey Coach Lane
Reading, MA 01867 / US
 [2021/32]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[2023/24]
Former [2021/32]Ehlich, Eva Susanne
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date21155644.405.02.2021
[2021/32]
Priority number, dateUS202062970828P06.02.2020         Original published format: US 202062970828 P
WO2020US2983024.04.2020         Original published format: PCT/US2020/029830
US202163136305P12.01.2021         Original published format: US 202163136305 P
US202163139123P19.01.2021         Original published format: US 202163139123 P
[2021/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3861985
Date:11.08.2021
Language:EN
[2021/32]
Type: B1 Patent specification 
No.:EP3861985
Date:14.06.2023
Language:EN
[2023/24]
Search report(s)(Supplementary) European search report - dispatched on:EP13.07.2021
ClassificationIPC:A61K9/00, A61K47/34, A61K47/10, A61K47/12
[2021/32]
CPC:
A61K9/0024 (EP,IL,KR); A61K31/216 (IL,US); A61K9/0051 (EP,CN,IL,KR,US);
A61K31/5575 (CN,IL,KR,US); A61K47/10 (EP,CN,IL,KR,US); A61K47/12 (EP,CN,IL);
A61K47/34 (CN,IL,KR); A61K47/6903 (IL,US); A61K47/6937 (IL,US);
A61K9/0048 (IL,US); A61K9/06 (CN,IL); A61K9/146 (CN,IL,US);
A61P27/02 (CN,IL,KR); A61P27/06 (CN,IL,KR,US); C08L67/04 (IL,US);
C08L2201/06 (IL,US); C08L2312/00 (IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/36]
Former [2021/32]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON AUGENERKRANKUNGEN[2021/32]
English:COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES[2021/32]
French:COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES OCULAIRES[2021/32]
Examination procedure29.04.2021Examination requested  [2021/32]
13.07.2021Date on which the examining division has become responsible
11.08.2021Despatch of a communication from the examining division (Time limit: M04)
21.12.2021Reply to a communication from the examining division
21.02.2022Despatch of a communication from the examining division (Time limit: M04)
04.07.2022Reply to a communication from the examining division
12.08.2022Despatch of a communication from the examining division (Time limit: M04)
21.11.2022Reply to a communication from the examining division
07.02.2023Communication of intention to grant the patent
15.03.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.04.2023Communication of intention to grant the patent
09.05.2023Fee for grant paid
09.05.2023Fee for publishing/printing paid
09.05.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23172380.0  / EP4252776
Opposition(s)15.03.2024No opposition filed within time limit [2024/21]
Fees paidRenewal fee
27.02.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY05.02.2021
HU05.02.2021
BG14.06.2023
CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
MC14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
TR14.06.2023
GR15.09.2023
IS14.10.2023
[2026/05]
Former [2025/41]CY05.02.2021
HU05.02.2021
BG14.06.2023
CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
MC14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2025/37]CY05.02.2021
BG14.06.2023
CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
MC14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/51]BG14.06.2023
CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
MC14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/45]CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
MC14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/27]CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SI14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/10]CZ14.06.2023
EE14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
PL14.06.2023
RO14.06.2023
RS14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/09]CZ14.06.2023
HR14.06.2023
LT14.06.2023
LV14.06.2023
RS14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
IS14.10.2023
Former [2024/08]HR14.06.2023
LT14.06.2023
LV14.06.2023
RS14.06.2023
SK14.06.2023
SM14.06.2023
GR15.09.2023
Former [2024/01]HR14.06.2023
LT14.06.2023
LV14.06.2023
RS14.06.2023
GR15.09.2023
Former [2023/51]HR14.06.2023
RS14.06.2023
GR15.09.2023
Former [2023/50]GR15.09.2023
Documents cited:Search[XI] WO2018058048  (INCEPT LLC et al.)
 [X] WO2016183296  (INCEPT LLC et al.)
 [A] WO2017015675  (ENVISIA THERAPEUTICS INC et al.)
 [A] WO2017019773  (LAYERBIO INC et al.)
 [X] WO2013039706  (INCEPT LLC et al.)
by applicant  SIMMONS, S., T.: "Ophthalmic Formulations", GLAUCOMA TODAY SUPPLEMENT TO ADVANCED OCULAR CARE, 2010
   THE EYE DISEASE PREVALENCE GROUP.: "Prevalence of open-angle glaucoma among adults in the United States", ARCH OPHTHALMOL, vol. 122, 2004, pages 532 - 538
   QUIGLEY, H.A.A.T. BROMAN: "The number of people with glaucoma worldwide", BR J OPHTHALMOL, vol. 90, no. 3, 2010, pages 262 - 7
   THAM, Y.-C. ET AL.: "Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040", OPHTHALMOLOGY, vol. 121, no. 11, 2014, pages 2081 - 2090
   AL-JAZZAF, A.M.L. DESANTISP.A. NETLAND: "Travoprost: a potent ocular hypotensive agent", DRUGS TODAY (BARE, vol. 39, no. 1, 2003, pages 61 - 74
   LIM, K.S. ET AL.: "Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects", A CROSSOVER STUDY. OPHTHALMOLOGY, vol. 115, no. 5, 2008, pages 790 - 795, XP022627722, DOI: 10.1016/j.ophtha.2007.07.002

DOI:   http://dx.doi.org/10.1016/j.ophtha.2007.07.002
   TORIS, C.B.B.A.T. GABELTP.L. KAUFMAN: "Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction", SURVEY OF OPHTHALMOLOGY, vol. 53, 2008, pages S107 - S120, XP025691111, DOI: 10.1016/j.survophthal.2008.08.010

DOI:   http://dx.doi.org/10.1016/j.survophthal.2008.08.010
   KHOLDEBARIN, R. ET AL.: "Multicenter study of compliance and drop administration in glaucoma", CAN J OPHTHALMOL, vol. 43, no. 4, 2008, pages 454 - 61
   FRIEDMAN, D.S. ET AL.: "Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 48, no. 11, 2007, pages 5052 - 5057
   NORDSTROM, B.L. ET AL.: "Persistence and Adherence With Topical Glaucoma Therapy", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 140, no. 4, 2005, pages 598e1 - 598e11, XP005193475, DOI: 10.1016/j.ajo.2005.04.051

DOI:   http://dx.doi.org/10.1016/j.ajo.2005.04.051
   YELLEPEDDI, V.K.S. PALAKURTHI: "Recent Advances in Topical Ocular Drug Delivery", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 32, no. 2, 2015, pages 67 - 82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.